The DOI matches its Crossref record; 47 of the 47 references it cites were found in a registry or an index.
A Placebo-Controlled Trial of D-Cycloserine Added to Conventional Neuroleptics in Patients With Schizophrenia
Abstract
BACKGROUND: In a preliminary dose-finding study, D-cycloserine, a partial agonist at the glycine modulatory site of the glutamatergic N-methyl-D-aspartate (NMDA) receptor, improved negative symptoms and cognitive function when added to conventional neuroleptics at a dose of 50 mg/d. METHODS: Forty-seven patients with schizophrenia meeting criteria for deficit syndrome were randomized to D-cycloserine, 50 mg/d (n=23) or placebo (n=24) added to their conventional neuroleptic for an 8-week, double-blind trial. Clinical assessments were performed at baseline and at weeks 1, 2, 4, 6, and 8. Serum concentrations of D-cycloserine, relevant amino acids, and homovanillic acid were assayed at baseline and at weeks 4 and 8. A cognitive battery was performed at baseline and at week 8. RESULTS: Thirty-nine patients completed the 8-week trial. Seven dropouts occurred in the D-cycloserine group and 1 in the placebo group. The mean reduction in negative symptoms with D-cycloserine (23%) was significantly greater than with placebo (7%) as calculated by slopes representing Scale for the Assessment of Negative Symptoms (SANS) total scores. Improvement of negative symptoms was predicted by low neuroleptic dose and low baseline SANS total score. No differences were found in performance on any cognitive test between groups or in changes in any other clinical measure. Clinical response did not correlate significantly with serum amino acid concentrations at baseline or with concentrations of D-cycloserine at weeks 4 and 8. CONCLUSION: These results support the hypothesis that agents acting at the glycine modulatory site of the NMDA receptor improve primary negative symptoms.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Statistical power analysis for the behavioral sciences
(1990) · Computers, Environment and Urban Systems · doi:10.1016/0198-9715(90)90050-4 · Cited by 65,269
Statistical Power Analysis for the Behavioral Sciences (2nd ed.).
Lachenbruch, P. A., & Cohen, J. (1989) · Journal of the American Statistical Association · doi:10.2307/2290095 · Cited by 37,395
The Positive and Negative Syndrome Scale (PANSS) for schizophrenia.
Kay, S. R., Fiszbein, A., & Opler, L. A. (1987) · Schizophrenia Bulletin · doi:10.1093/schbul/13.2.261 · Cited by 21,378
Statistical Analysis With Missing Data
Lahiff, M., Little, R. J. A., & Rubin, D. B. (1989) · Journal of the American Statistical Association · doi:10.2307/2289883 · Cited by 17,265
Random-Effects Models for Longitudinal Data
Laird, N. M., & Ware, J. H. (1982) · Biometrics · doi:10.2307/2529876 · Cited by 8,923
(1976) · Medical Entomology and Zoology · Cited by 8,899
High-speed scanning in human memory
Sternberg, S. (1966) · Science · doi:10.1126/science.153.3736.652 · Cited by 3,576
Krystal, J. H. (1994) · Archives of General Psychiatry · doi:10.1001/archpsyc.1994.03950030035004 · Cited by 3,330
Recent advances in the phencyclidine model of schizophrenia
(1991) · American Journal of Psychiatry · doi:10.1176/ajp.148.10.1301 · Cited by 2,904
Glutamate receptor dysfunction and schizophrenia
Olney, J. W. (1995) · Archives of General Psychiatry · doi:10.1001/archpsyc.1995.03950240016004 · Cited by 1,685 · cited 1×
“R ECENT EFFORTS to direct pharmacological intervention at the N-methyl-Daspartate (NMDA) subtype of glutamate receptor have followed from evidence linking this receptor complex to schizophrenia.(1,2) For example, phencyclidine and ketamine, noncompetitive antagonists at the NMDA receptor complex, produce positive and…”
Background
Cited by
Glutamate receptor ion channels
Mayer, M. L. (2005) · Current Opinion in Neurobiology · doi:10.1016/j.conb.2005.05.004 · Cited by 3,640
Glutamate Receptor Ion Channels: Structure, Regulation, and Function
Traynelis, S. F., Wollmuth, L. P., McBain, C. J., Menniti, F. S., Vance, K. M., Ogden, K. K., Hansen, K. B., Yuan, H., Myers, S. J., & Dingledine, R. (2010) · Pharmacological Reviews · doi:10.1124/pr.109.002451 · Cited by 3,568
Ressler, K. J., Rothbaum, B. O., Tannenbaum, L., Anderson, P., Graap, K., Zimand, E., Hodges, L., & Davis, M. (2004) · Archives of General Psychiatry · doi:10.1001/archpsyc.61.11.1136 · Cited by 1,063
Miyamoto, S., Duncan, G. E., Marx, C. E., & Lieberman, J. A. (2005) · Molecular Psychiatry · doi:10.1038/sj.mp.4001556 · Cited by 988
Glutamate and Schizophrenia: Beyond the Dopamine Hypothesis
Coyle, J. T. (2006) · Cellular and Molecular Neurobiology · doi:10.1007/s10571-006-9062-8 · Cited by 917
“In a large parallel placebo-controlled trial, Goff et al. (1999) replicated the effects of D-cycloserine on negative symptoms in chronic schizophrenics receiving typical antipsychotics but not the cognitive effects (Goff et al., 1999).”
BackgroundResultSelf-citationThe Emerging Role of Glutamate in the Pathophysiology and Treatment of Schizophrenia
Goff, D. C., & Coyle, J. T. (2001) · American Journal of Psychiatry · doi:10.1176/appi.ajp.158.9.1367 · Cited by 915
Self-citationWalker, D. L., Ressler, K. J., Lu, K.-T., & Davis, M. (2002) · The Journal of Neuroscience · doi:10.1523/jneurosci.22-06-02343.2002 · Cited by 815
D-Alanine Added to Antipsychotics for the Treatment of Schizophrenia
Tsai, G. E., Yang, P., Chang, Y.-C., & Chong, M.-Y. (2006) · Biological Psychiatry · doi:10.1016/j.biopsych.2005.06.032 · Cited by 674
Self-citationCognitive deficits and functional outcome in schizophrenia
Bowie, C. R., & Harvey, P. D. (2006) · Neuropsychiatric Disease and Treatment · doi:10.2147/nedt.2006.2.4.531 · Cited by 647
Glutamatergic mechanisms in schizophrenia
Tsai, G., & Coyle, J. T. (2002) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.42.082701.160735 · Cited by 577
Self-citationD-serine added to antipsychotics for the treatment of schizophrenia
Tsai, G., Yang, P., Chung, L.-C., Lange, N., & Coyle, J. T. (1998) · Biological Psychiatry · doi:10.1016/s0006-3223(98)00279-0 · Cited by 571
Self-citationAugmentation of Exposure Therapy With D-Cycloserine for Social Anxiety Disorder
Hofmann, S. G., Meuret, A. E., Smits, J. A. J., Simon, N. M., Pollack, M. H., Eisenmenger, K., Shiekh, M., & Otto, M. W. (2006) · Archives of General Psychiatry · doi:10.1001/archpsyc.63.3.298 · Cited by 560
Javitt, D. C. (2007) · International Review of Neurobiology · doi:10.1016/s0074-7742(06)78003-5 · Cited by 560
Krystal, J. H., D'Souza, D. C., Mathalon, D., Perry, E., Belger, A., & Hoffman, R. (2003) · Psychopharmacology · doi:10.1007/s00213-003-1582-z · Cited by 530
Glutamate as a therapeutic target in psychiatric disorders
Javitt, D. C. (2004) · Molecular Psychiatry · doi:10.1038/sj.mp.4001551 · Cited by 524
A meta-analysis of D-cycloserine and the facilitation of fear extinction and exposure therapy
Norberg, M. M., Krystal, J. H., & Tolin, D. F. (2008) · Biological Psychiatry · doi:10.1016/j.biopsych.2008.01.012 · Cited by 510
Convergence of biological and psychological perspectives on cognitive coordination in schizophrenia
Phillips, W. A., & Silverstein, S. M. (2003) · Behavioral and Brain Sciences · doi:10.1017/s0140525x03000025 · Cited by 445
“Second, in patients whose glycine levels are initially sub-optimal, glycine agonists (which then facilitate NMDA-channel opening) can improve negative symptoms (Goff et al. 1999; Heresco-Levy et al. 1999).”
BackgroundPersistent Negative Symptoms in Schizophrenia: An Overview
Buchanan, R. W. (2007) · Schizophrenia Bulletin · doi:10.1093/schbul/sbl057 · Cited by 443
Converging Evidence of NMDA Receptor Hypofunction in the Pathophysiology of Schizophrenia
COYLE, J. T., TSAI, G., & GOFF, D. (2003) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1300.020 · Cited by 442
Self-citationBuchanan, R. W. (2005) · Schizophrenia Bulletin · doi:10.1093/schbul/sbi020 · Cited by 438
Glutamate, Dopamine, and Schizophrenia: From Pathophysiology to Treatment
LARUELLE, M., KEGELES, L. S., & ABI‐DARGHAM, A. (2003) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1300.063 · Cited by 437
Buchanan, R. W., Javitt, D. C., Marder, S. R., Schooler, N. R., Gold, J. M., McMahon, R. P., Heresco-Levy, U., & Carpenter, W. T. (2007) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2007.06081358 · Cited by 419
NMDA Receptor and Schizophrenia: A Brief History
Coyle, J. T. (2012) · Schizophrenia Bulletin · doi:10.1093/schbul/sbs076 · Cited by 410
Self-citationHeresco-Levy, U., Javitt, D. C., Ebstein, R., Vass, A., Lichtenberg, P., Bar, G., Catinari, S., & Ermilov, M. (2005) · Biological Psychiatry · doi:10.1016/j.biopsych.2004.12.037 · Cited by 386
Glutamate hypothesis in schizophrenia
Uno, Y., & Coyle, J. T. (2019) · Psychiatry and Clinical Neurosciences · doi:10.1111/pcn.12823 · Cited by 367
Self-citationTsai, G., Lane, H.-Y., Yang, P., Chong, M.-Y., & Lange, N. (2004) · Biological Psychiatry · doi:10.1016/j.biopsych.2003.09.012 · Cited by 342
Self-citationMolecular aspects of glutamate dysregulation: implications for schizophrenia and its treatment
Konradi, C., & Heckers, S. (2003) · Pharmacology & Therapeutics · doi:10.1016/s0163-7258(02)00328-5 · Cited by 336
l-Serine in disease and development
de KONING, T. J., SNELL, K., DURAN, M., BERGER, R., POLL-THE, B.-T., & SURTEES, R. (2003) · Biochemical Journal · doi:10.1042/bj20021785 · Cited by 295
Burgdorf, J., Zhang, X.-L., Nicholson, K. L., Balster, R. L., David Leander, J., Stanton, P. K., Gross, A. L., Kroes, R. A., & Moskal, J. R. (2013) · Neuropsychopharmacology · doi:10.1038/npp.2012.246 · Cited by 284
Lane, H.-Y., Chang, Y.-C., Liu, Y.-C., Chiu, C.-C., & Tsai, G. E. (2005) · Archives of General Psychiatry · doi:10.1001/archpsyc.62.11.1196 · Cited by 271
Self-citationHigh-dose glycine added to olanzapine and risperidone for the treatment of schizophrenia
Heresco-Levy, U., Ermilov, M., Lichtenberg, P., Bar, G., & Javitt, D. C. (2004) · Biological Psychiatry · doi:10.1016/s0006-3223(03)00707-8 · Cited by 222
Prepulse inhibition and genetic mouse models of schizophrenia
Powell, S. B., Zhou, X., & Geyer, M. A. (2009) · Behavioural Brain Research · doi:10.1016/j.bbr.2009.04.021 · Cited by 218
“D-cycloserine has been shown to improve negative symptoms when added to antipsychotic therapy in some clinical trials [72,73], but failed to show improvement in other trials [71,206].”
ResultA Pilot Study of d-Cycloserine in Subjects With Autistic Disorder
Posey, D. J., Kem, D. L., Swiezy, N. B., Sweeten, T. L., Wiegand, R. E., & McDougle, C. J. (2004) · American Journal of Psychiatry · doi:10.1176/appi.ajp.161.11.2115 · Cited by 199
Marx, C. E., Keefe, R. S. E., Buchanan, R. W., Hamer, R. M., Kilts, J. D., Bradford, D. W., Strauss, J. L., Naylor, J. C., Payne, V. M., Lieberman, J. A., et al. (2009) · Neuropsychopharmacology · doi:10.1038/npp.2009.26 · Cited by 193
Abi-Dargham, A., & Laruelle, M. (2005) · European Psychiatry · doi:10.1016/j.eurpsy.2004.11.003 · Cited by 179
Extinction memory is impaired in schizophrenia
Holt, D. J., Lebron-Milad, K., Milad, M. R., Rauch, S. L., Pitman, R. K., Orr, S. P., Cassidy, B. S., Walsh, J. P., & Goff, D. C. (2009) · Biological Psychiatry · doi:10.1016/j.biopsych.2008.09.017 · Cited by 170
GOFF, D., CATHER, C., GOTTLIEB, J., EVINS, A., WALSH, J., RAEKE, L., OTTO, M., SCHOENFELD, D., & GREEN, M. (2008) · Schizophrenia Research · doi:10.1016/j.schres.2008.08.012 · Cited by 144
“Previous trials in which glycine site agonists demonstrated efficacy for negative symptoms clearly displayed a gradual improvement in symptom ratings over time with a plateau after approximately 6 weeks (Goff et al., 1999b; Heresco-Levy et al., 1999; Tsai et al., 1998).”
InfluentialSelf-citationEarly interventions in risk groups for schizophrenia: what are we waiting for?
Sommer, I. E., Bearden, C. E., van Dellen, E., Breetvelt, E. J., Duijff, S. N., Maijer, K., van Amelsvoort, T., de Haan, L., Gur, R. E., Arango, C., et al. (2016) · npj Schizophrenia · doi:10.1038/npjschz.2016.3 · Cited by 140
D-Cycloserine in Neuropsychiatric Diseases: A Systematic Review
Schade, S., & Paulus, W. (2016) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyv102 · Cited by 135
Apathy in schizophrenia: clinical correlates and association with functional outcome
Kiang, M., Christensen, B. K., Remington, G., & Kapur, S. (2003) · Schizophrenia Research · doi:10.1016/s0920-9964(02)00433-4 · Cited by 118
Does D-cycloserine enhance exposure therapy for anxiety disorders in humans? A meta-analysis
Rodrigues, H., Figueira, I., Lopes, A., Gonçalves, R., Mendlowicz, M. V., Coutinho, E. S. F., & Ventura, P. (2014) · PLoS ONE · doi:10.1371/journal.pone.0093519 · Cited by 109
D-cycloserine facilitation of cognitive behavioral therapy for delusions in schizophrenia
Gottlieb, J. D., Cather, C., Shanahan, M., Creedon, T., Macklin, E. A., & Goff, D. C. (2011) · Schizophrenia Research · doi:10.1016/j.schres.2011.05.029 · Cited by 73
Self-citationThe neuroanatomy of schizophrenia: circuitry and neurotransmitter systems
Fallon, J. H., Opole, I. O., & Potkin, S. G. (2003) · Clinical Neuroscience Research · doi:10.1016/s1566-2772(03)00022-7 · Cited by 53
Otto, M. W., Basden, S. L., Leyro, T. M., McHugh, R. K., & Hofmann, S. G. (2007) · CNS Spectrums · doi:10.1017/s1092852900020526 · Cited by 53
Minichino, A., Brondino, N., Solmi, M., Del Giovane, C., Fusar-Poli, P., Burnet, P., Cipriani, A., & Lennox, B. R. (2021) · Schizophrenia Research · doi:10.1016/j.schres.2020.02.012 · Cited by 50
Treatment of Comorbid Tuberculosis and Depression
Trenton, A. J., & Currier, G. W. (2001) · The Primary Care Companion For CNS Disorders · doi:10.4088/pcc.v03n0610 · Cited by 48
Emerging drugs for the treatment of symptoms associated with autism spectrum disorders
Wink, L. K., Plawecki, M. H., Erickson, C. A., Stigler, K. A., & McDougle, C. J. (2010) · Expert Opinion on Emerging Drugs · doi:10.1517/14728214.2010.487860 · Cited by 36
Egerton, A., Fusar-Poli, P., & M. Stone, J. (2012) · Current Pharmaceutical Design · doi:10.2174/138161212799316244 · Cited by 36
Kuppili, P. P., Menon, V., Sathyanarayanan, G., Sarkar, S., & Andrade, C. (2021) · Journal of Neural Transmission · doi:10.1007/s00702-020-02292-x · Cited by 16
Metadata
- Authors
- Goff, D. C., Tsai, G., Levitt, J., Amico, E., Manoach, D., Schoenfeld, D. A., Hayden, D. L., McCarley, R., & Coyle, J. T.
- Venue
- Archives of General Psychiatry
- Publisher
- American Medical Association (AMA)
- Published
- 1999-01-01
- Volume
- 56
- Issue
- 1
- Pages
- 21
- ISSN
- 0003-990X (ISSN-L)
- OpenAlex
- W2078790185
- Cited by
- 436
- References
- 47
- FWCI
- 15.12
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.